Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Madharry who wrote (9290)	10/10/2003 8:56:47 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

<GENR> Well I actually bought a very small position when the results of their trial were released. One data point is that PFE paid big bucks to Eyetech for Macugen ($100m upfront and up to $500m biobucks). The squalamine results were very strong, assuming one can believe them, that is. And if the drug works for macular degeneration it might also work in other anti-angiogenesis applications - I guess the hope is that it has wider coverage than the pure anti-VEGF drugs. The concerns are obvious - Mexican trials and no cash. But as a small part of a basket of other stocks it may be worth a flier. Peter